Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11M | -12M | -4M | -854K | -138K |
| EBITDA | -11M | 48K | -11M | 0 | 0 |
| Net Income | -10M | -17M | -13M | -854K | -138K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.42
+13.60% today
1Y Change
-23.08%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $1.42 and down 23.1% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +41.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +41.1%, free cash flow +27.3% with operating margin 0.0% and ROIC -178.2%. Stock Foundry combines TELO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TELO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TELO Max Drawdown
-52.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TELO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$138.1K
+83.8% YoY
Free Cash Flow
-$119.4K
+74.5% YoY
Revenue Growth
+0.0%
EPS Growth
+41.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11M | -12M | -4M | -854K | -138K |
| EBITDA | -11M | 48K | -11M | 0 | 0 |
| Net Income | -10M | -17M | -13M | -854K | -138K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 1M | 1K | 1K | 0 |
| Total Assets | 7M | 1M | 5M | 49K | 55K |
| Total Liabilities | 1M | 681K | 1M | 986K | 138K |
| Shareholder Equity | 6M | 643K | 3M | -937K | -83K |
| Total Debt | 0 | 93K | 101K | 582K | 0 |
| Net Debt | -7M | -1M | 100K | 580K | 0 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
119K
+74.5% YoY
Capital Expenditures
4
Free Cash Flow
119K
+74.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-315.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.